Cure My Disease

Don't miss your cure!

 Log in / Sign up

Gut bacteria capsules take on superbugs in antibiotic patients

NCT ID NCT07496502

Disease control Sponsor: Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether taking capsules containing healthy gut bacteria could help clear drug-resistant germs (including C. difficile) from the intestines of 42 hospitalized adults who needed at least 7 days of antibiotics. Participants received either the bacteria capsules or a placebo, and researchers checked stool samples 14 days later for the resistant germs. The goal was to see if this approach is safe and effective at reducing these hard-to-treat infections.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

42 people

The number who actually took part.

Started

Mar 2022

Finished

Jul 2022

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult patients (≥18 years old). * Hospitalized and scheduled to receive systemic antibiotic therapy for a minimum expected duration of 7 days. * Able to provide written informed consent. Exclusion Criteria: * Severe immunodeficiency (e.g., absolute neutrophil count \<500/µL, solid organ transplant within 6 months, active hematologic malignancy on chemotherapy). * Pregnancy or breastfeeding. * Life expectancy \< 3 months. * History of total colectomy or ileostomy. * Known hypersensitivity or allergy to any component of the study capsules. * Inability to swallow capsules.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Clostridioides difficile infection are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Clostridium difficile colitis Clostridium infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Clostridioides difficile infection Drug resistance, bacterial Gastrointestinal microbiome Microbiota Multidrug-resistant colonization

Contacts and locations

Locations

  • Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran

    Mexico City, Mexico City, 14080, Mexico

More trials for these conditions

Other studies related to the condition(s) this trial covers.